Drug Profile
Research programme: cancer vaccine - Shanghai Genomics
Alternative Names: PRO-VAXLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Shanghai Genomics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 20 Jun 2005 Shanghai Genomics has been acquired by GNI
- 17 Mar 2004 Preclinical trials in Cancer in China (unspecified route)